The North American veterinary vaccines market is estimated to be worth USD 2.68 Billion by 2028 from USD 2.11 Billion in 2023, growing at a CAGR of 4.93% from 2023 to 2028.
The growing number of animals suffering from infectious and chronic diseases primarily drives the veterinary vaccines market in North America. For instance, the growing rates of zoonotic disease from animals like salmonella is one of the most common causes of zoonotic outbreaks in the United States. Owing to the increasing number of chronic diseases, pet owners and livestock owners are taking pet insurance to reduce the cost of treatment, diagnosis, and vaccination. As a result, to prevent these chronic diseases, vaccines play a significant role. In addition, the growing consumption of non-vegetarian food and milk products from the North American population resulted in the growing animal vaccine production. Animals are the primary sources of most common foods like meat, milk, leather, wool, and proteins.
The growing R&D around veterinary vaccines and increasing support from the North American governments are anticipated to support the growth rate of the North American market. Due to increasing the focus on food safety and the safety of the animals, the manufacturers have increased the modifications to a vaccine, making different combinations in attempts for an effective vaccine. Increasing clinical centers for clinical vaccine trials also help develop the market in the North American region.
The growing pet ownership in North American countries and rising pet care expenditure are anticipated to grow the veterinary vaccines market in North America. An estimated 6.3 million pets are adopted annually in the U.S. The adoption rate has increased during the COVID-19 pandemic for a companion or security reasons. As a result, pet owners show interest in pet healthcare by taking regular check-ups and vaccinating their pets to prevent the virus from attacking. In addition, pet insurance and increasing awareness programs for the registration of pet vaccination in the region propels the North American veterinary vaccines market.
On the other hand, the high investments required to manufacture veterinary vaccines slightly hamper North America's market growth. Furthermore, side effects associated with the usage of vaccines on animals, poor infrastructure facilities in some countries, the high costs of some vaccines, and the unavailability of the drugs in some countries are further showcasing negative impacts on the veterinary vaccines market growth in North America. In addition, the scarcity of skilled professionals limits the market’s growth rate in North America.
This research report on the North American veterinary vaccines market has been segmented and sub-segmented into the following categories:
Based on technology, the canine vaccines segment accounted for a slightly larger share (in terms of revenue) than the feline vaccines segment due to the higher average cost allied with canine vaccination. Similarly, the bovine vaccines sub-segment accounted for the largest share (in terms of revenue), followed by porcine.
North America accounted for the most significant worldwide market share in 2022. The increasing advancements drive the growth of the North American market in animal healthcare and healthcare expenditures.
The U.S. held a significant share of the North American market in 2022 and the domination of the U.S. market is expected to continue in the North American market during the forecast period owing to the growing manufacturing of novel drugs for animal welfare. In 2020, The United States Department of Agriculture's Animal and Plant Health Inspection Service announced the investment in developing vaccines for animals that helps in preventing infections. In addition, they increased their investment in coming years which helps to control the spread of infection by reducing the virus shed by animals. The growing number of pharmaceutical companies for animal drugs is contributing to the growth of the U.S. market. In addition, owing to the growing pet adoption, pharma companies are interested in manufacturing different kinds of vaccines for different animals.
Canada is another potential regional market for veterinary vaccines in the North American region and is estimated to grow at a healthy CAGR during the forecast period. In Canada, veterinary vaccines are regulated by the Canadian Food Inspection Agency. As a result, several regulations have been taken to manufacture a vaccine for animals such as domestic livestock, poultry, pets, wildlife, and fish. In addition, the Canadian government has focused on developing a plant-based animal vaccine to reduce the vaccine's side effects.
KEY MARKET PLAYERS:
A few of the prominent companies operating in the North American Veterinary / Animal Healthcare Market profiled in this report are Bayer HealthCare AG, Bioniche Animal Health Canada, Sanofi Animal Health Inc., Biogenesis Bago SA, Heska Corporation, Indian Immunologicals Ltd., Boehringer Ingelheim GmbH, Zoetis, Novartis Animal Health Inc., Merck & Co Inc., and Protein Sciences.
The North America veterinary vaccines market is estimated to grow at a CAGR of 4.93% from 2023 to 2028.
Zoetis Inc., Boehringer Ingelheim International GmbH, Merck & Co., Inc., and Elanco Animal Health are some of the notable companies in the North American veterinary vaccines market.
The development of new vaccines for emerging and neglected animal diseases, increasing adoption of vaccination programs by livestock producers, and the rising demand for personalized and customized veterinary healthcare services are some of the lucrative opportunities in the North America veterinary vaccines market.
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2000
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: firstname.lastname@example.org